Impact of Class Actions on Pharmaceutical Oversight: US, Israeli and French Perspectives
A colleague recently drew my attention to the proposition that “in the United States, the specter of class-action lawsuits imposes a higher level of precaution on the part of drug makers.” This statement was made in a newspaper article that discussed the scandal that erupted in France in connection with the prescription drug Mediator, which was …
